SciELO - Scientific Electronic Library Online

vol.37 número3Hemorragia pulmonar en paciente con nefropatía IgASerratia marcescens, Morganella morganii, Klebsiella oxytoca relacionados con ataques de peritonitis en un paciente en diálisis peritoneal automatizada: Un caso índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados




Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google


Nefrología (Madrid)

versión On-line ISSN 1989-2284versión impresa ISSN 0211-6995

Nefrología (Madr.) vol.37 no.3 Cantabria may./jun. 2017 

Letter to the Editor

Hypertensive pulmonary edema related to desmopressin acetate

Edema pulmonar hipertensivo relacionado con el acetato de desmopresina

Ummu Korkmaz1  , Erol Demir1  , Halil Yazici1  , Mehmet Sukru Sever1 

1Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey

Dear Editor,

Desmopressin acetate, known as DDVAP (1-deamino-8-D-arginine vasopressin), increases factors VIII and vWF, shortens activated partial thrombin time and bleeding time. Desmopressin is the best treatment in emergency situation, increases the release of the von Willebrand factor from the endothelium in uremic bleeding.1 Potential side effects of desmopressin include headache, nausea, malaise, hypotension, facial flushing, tachycardia, dizziness and hyponatremia.2 However hypertension weren’t defined before, we present two cases of hypertensive pulmonary edema after the infusion of desmopressin prior to ultrasound (USG) guided percutaneous kidney biopsy.

A 49 year-old female with end-stage renal failure secondary to unknown etiology received a living-donor transplant 3 years ago, was scheduled to have a transplant biopsy due to deteriorating graft function. Blood pressure was 160/90 mmHg, pulse was 72 beats/min, and respiratory rate was 14 breaths/min.

She was given an infusion of 15 μg of intravenous DDAVP over 20 min in preparation for biopsy. Biopsy performed without complications. After 40 min from the infusion; the patient suffers from dyspnea. Her blood pressure elevated to 220/140 mmHg. On examination there was crepitation on the both lungs on every area. SPO2 was 70 on the pulse oximeter.

Respiratory rate was elevated to 40. Immediately she was given furosemide and nitroglycerin infusion with oxygen. Her SPO2 levels elevated after the treatment. She was monitoring all day and her blood pressure fall to 140/80 after 8 h.

A 42 year-old male with crescentic IgA nephropathy, who was diagnosed 7 months ago, was treated with pulse steroid and cyclophosphamide for induction. On examination, the patient was relieve, body temperature was 36.6C, blood pressure was 150/90 mmHg, pulse was 72 beats/min, and respiratory rate was 14 breaths/min.

He was given an infusion of 15 μg of intravenous DDAVP over 20 min in preparation for biopsy. Biopsy performed without complications. After 2 h from the infusion; the patient suffers from dyspnea. His blood pressure elevated to 230/120 mmHg. He was treated with oxygen, furosemide and nitroglycerin. His blood pressure was 150/90 mmHg after 8 h of intense therapy. His oxygen saturation had risen to 98 from 75 on room air.

Both of cases didn’t have any history of coronary heart disease or heart failure but they have hypervolemia due to renal failure.

Hergesell et al. reported that risks in order to minimize, to adopt adequate biopsy technique is not only important, but also high-risk patients, especially uncontrolled blood pressure, with a clotting disorder, or has emphasized that it is necessary to exclude those unwilling to cooperate.3 Mannucci et al. reported that prohibited for use in who have arterial disease. DDAVP related myocardial infarction and cerebrovascular disease has been reported to case presentations, can’t be used in patients with known cardiovascular disease.4

DDAVP was an analog of vasopressin, may provoke symptomatic hyponatremia because of water retention. According to the U.S. Food and Drug Administration Agency, the half-life of DDAVP in patients with severe renal impairment can be extend by 9 h. Therefore, patients should be advised to restrict fluid intake from 1 h before to 9 h after administration of DDAVP. Blood sodium control is proposed following use in hyponatremic patient.5,6

There are no publications that specify the use of DDAVP in hypervolemic patient. In our cases DDAVP effected like vasopressin and increased water retention in the hypervolemic patients. In patients without structural heart disease DDAVP may have a role that could lead to hypertensive pulmonary edema. In our patients; increased blood pressure responded diuretic and vasodilator treatment.

Hypertension is not a limiting factor to evaluate the use of DDAVP because of falsely elevated blood pressure due to anxiety. We recommend careful use of DDAVP in hypertensive patients due to a hypervolemia without structural heart disease, and we think this situation could lead role in the hypertensive pulmonary edema.


1. Manno C, Bonifati C, Torres DD, Campobasso N, Schena FP. Desmopressin acetate in percutaneous ultrasound-guided kidney biopsy: a randomized controlled trial. Am J Kidney Dis. 2011;57:850-5. [ Links ]

2. Stoof SC, Cnossen MH, de Maat MP, Leebeek FW, Kruip MJ. Side effects of desmopressin in patients with bleeding disorders. Haemophilia. 2016;22:39-45. [ Links ]

3. Hergesell O, Felten H, Andrassy K, Kühn K, Ritz E. Safety of ultrasound-guided percutaneous renal biopsy: retrospective analysis of 1,090 consecutive cases. Nephrol Dial Transplant. 1998;13:975-7. [ Links ]

4. Mannucci PM, Vicente V, Alberca I, Sacchi E, Longo G, Harris AS, et al. Intravenous and subcutaneous administration of desmopressin (DDAVP) to hemophiliacs: pharmacokinetics and factor VIII responses. Thromb Haemost. 1987;58:1037-9. [ Links ]

5. FDA ALERT [12/4/2007]: Desmopressin acetate (marketed as DDAVP nasal spray, DDAVP rhinal tube, DDAVP, DDVP, minirin, and stimate nasal spray). [ Links ]

6. Bertholini DM, Butler CS. Severe hyponatraemia secondary to desmopressin therapy in von Willebrand's disease. Anaesth Intensive Care. 2000;28:199-201. [ Links ]

Corresponding author. E-mail address: (E. Demir).

Creative Commons License This is an open-access article distributed under the terms of the Creative Commons Attribution License